Running title: Chiral status of withdrawn drugs
Ayfer Bahar1*, Volkan Aydin2*, Caner
Vizdiklar1, Ahmet Akici1
Department of Medical Pharmacology, School of Medicine, Marmara
University, Istanbul, Turkey
Department of Medical Pharmacology, International School of Medicine,
Istanbul Medipol University, Istanbul, Turkey
* The authors equally contributed to this paper.
Correspondence: Prof Ahmet Akici, MD
Department of Medical Pharmacology, Marmara University School of
Medicine, Maltepe 34854, Istanbul, Turkey.
Phone: +902165557700; e-mail:aakici@marmara.edu.tr
Ethical approval: This study was approved by Ethics Committee
for Non-interventional Clinical Studies of Marmara University Institute
of Health Sciences (Approval number: 16.11.2020-91).
Acknowledgements : We thank to Dr. Igho Onakpoya and his
co-workers for their tremendous efforts and earlier studies on withdrawn
drugs that inspired us to investigate another aspect of the subject.
Competing Interests: The authors declare they have no competing
or conflict of interest.
Funding: This research did not receive any specific grant from
funding agencies in the public, commercial, or not-for-profit sectors.
Contributions: Conception and design: AB, AA, VA; Acquisition
of data: AB, CV, VA; Analysis and interpretation of data: VA, AB, CV;
Writing first draft: VA, AB, CV, AA; Critical review and supervision:
AA, VA; Final approval to the submitted version of the manuscript: AB,
VA, CV, AA.
Data availability: The data that support the findings of this
study are available from the corresponding author upon reasonable
request.
Keywords: pharmacovigilance, pharmacoepidemiology, drug
regulation, stereoisomerism
Word count: 2682, Table count: 4, Figure
count: 1